According to our (Global Info Research) latest study, the global Connected Continuous Glucose Monitoring Systems market size was valued at US$ 14868 million in 2025 and is forecast to a readjusted size of US$ 33059 million by 2032 with a CAGR of 11.5% during review period.
Connected Continuous Glucose Monitoring systems are wearable or implantable glucose-monitoring device systems designed for diabetes management, insulin therapy support, remote patient monitoring and broader metabolic health use cases. A typical system combines a glucose sensor, a transmitter or all-in-one sensor module, a receiver or smartphone application, embedded algorithms and cloud-enabled data connectivity. By measuring glucose levels in interstitial fluid at frequent intervals, CGM systems provide real-time or near-real-time glucose readings, trend arrows, time-in-range metrics, hyperglycemia and hypoglycemia alerts, and downloadable or shareable data reports. The core value of a connected CGM system lies in continuous data generation and connected decision support rather than in a single point-in-time glucose measurement.
Based on our research, connected CGM systems have moved beyond the narrow role of a specialist monitoring tool for insulin-intensive patients and are becoming a core data infrastructure for diabetes care, remote patient management and metabolic health applications. The industry should not be understood merely as a sensor hardware market. Its real value chain combines recurring sensor consumables, connected transmitters or all-in-one patches, mobile applications, cloud-based analytics, alerts and data reports that support clinical decisions and patient behavior change. Under the narrow scope adopted in this report, the market includes validated CGM sensor systems and directly bundled connectivity and software functions, while avoiding the inclusion of finger-stick blood glucose meters, stand-alone diabetes apps, insulin pump hardware revenue and unapproved consumer wearable glucose claims. The regulatory distinction between authorized CGM products and non-authorized glucose claims made by smartwatches or rings is important for defining a reliable market boundary.
Demand growth is broadening. The first major base remains Type 1 diabetes and insulin-treated Type 2 diabetes, but the incremental growth pool is increasingly linked to non-insulin Type 2 diabetes, pregnancy-related glucose monitoring, remote patient monitoring, pharmacy-led patient education and OTC metabolic health use cases. The emergence of OTC CGM products in the United States indicates that CGM is starting to move from a prescription-only therapeutic device into a wider category of medical-grade connected biosensors. However, this expansion also introduces new risks: lower average selling prices, more consumer-oriented channels, heavier marketing costs, and the need to prove that broader metabolic-health usage can translate into sustainable clinical or behavioral value.
From a technology-route perspective, subcutaneous electrochemical enzyme-based sensors remain the mainstream architecture. The competitive focus is shifting from basic glucose measurement toward longer wear time, calibration-free performance, smaller patch size, more reliable Bluetooth connectivity, better alarm accuracy, cloud integration, AI-based prediction and interoperability with automated insulin delivery systems. Implantable CGM provides a differentiated long-duration route but requires procedure-based adoption and a dedicated commercial model. Non-invasive glucose monitoring continues to attract attention, yet most players remain in the development or limited commercialization stage and should not be treated as equivalent to approved mainstream CGM systems. Over the next decade, the industry is likely to evolve into a three-layer structure: global platform leaders, fast-iterating regional challengers and smaller differentiated technology companies.
This report is a detailed and comprehensive analysis for global Connected Continuous Glucose Monitoring Systems market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Connected Continuous Glucose Monitoring Systems market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Connected Continuous Glucose Monitoring Systems market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Connected Continuous Glucose Monitoring Systems market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Connected Continuous Glucose Monitoring Systems market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Connected Continuous Glucose Monitoring Systems
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Connected Continuous Glucose Monitoring Systems market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott Laboratories, DexCom, Inc., Medtronic plc, F. Hoffmann-La Roche Ltd, Jiangsu Yuyue Medical Equipment & Supply Co., Ltd., Sinocare Inc., SIBIONICS, MicroTech Medical (Hangzhou) Co., Ltd., Medtrum Technologies Inc., Senseonics Holdings, Inc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Connected Continuous Glucose Monitoring Systems market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Wearable Patch CGM
Implantable CGM
Other
Market segment by Sensor Technology
Electrochemical Enzymatic Sensor
Fluorescence-based Sensor
Non-invasive Sensor
Other Sensor Technology
Market segment by Wear Duration
Up to 10 Days
11–15 Days
16–31 Days
More than 90 Days
Other
Market segment by Regulatory Positioning
Prescription CGM
OTC CGM
Market segment by Application
Professional Clinical Monitoring
Metabolic Health Management
Research and Clinical Trial Use
Other
Major players covered
Abbott Laboratories
DexCom, Inc.
Medtronic plc
F. Hoffmann-La Roche Ltd
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
Sinocare Inc.
SIBIONICS
MicroTech Medical (Hangzhou) Co., Ltd.
Medtrum Technologies Inc.
Senseonics Holdings, Inc.
i-SENS, Inc.
Bionime Corporation
Biolinq Incorporated
FiberSense AG
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Connected Continuous Glucose Monitoring Systems product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Connected Continuous Glucose Monitoring Systems, with price, sales quantity, revenue, and global market share of Connected Continuous Glucose Monitoring Systems from 2021 to 2026.
Chapter 3, the Connected Continuous Glucose Monitoring Systems competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Connected Continuous Glucose Monitoring Systems breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Connected Continuous Glucose Monitoring Systems market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Connected Continuous Glucose Monitoring Systems.
Chapter 14 and 15, to describe Connected Continuous Glucose Monitoring Systems sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Connected Continuous Glucose Monitoring Systems. Industry analysis & Market Report on Connected Continuous Glucose Monitoring Systems is a syndicated market report, published as Global Connected Continuous Glucose Monitoring Systems Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Connected Continuous Glucose Monitoring Systems market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.